Insilico Medicine Added to Hang Seng Biotech Index, Effective 8 June 2026

Bulletin Express

05/26

Insilico Medicine Cayman TopCo (Insilico Medicine) announced that Hang Seng Indexes Company Limited will include the company as a constituent of the Hang Seng Biotech Index following its first-quarter 2026 review. The adjustment will be implemented after market close on 5 June 2026 and take effect on 8 June 2026.

The Hang Seng Biotech Index tracks the performance of the 30 largest biotech companies listed in Hong Kong that are eligible for Southbound Stock Connect trading. Insilico Medicine’s inclusion signals growing market recognition of its long-term growth prospects and is expected to broaden exposure to index-tracking and institutional portfolios, potentially enhancing share liquidity and investor diversification.

The Board expressed appreciation for shareholder support and reiterated that forward-looking statements are subject to uncertainties. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares. The announcement was dated 26 May 2026 and signed by Chairman, Executive Director, CEO and CBO, Dr. Aleksandrs Zavoronkovs.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1176084051"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176084051\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176084051?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176084051","market":"hk","top_or_hot":-1,"title":"Insilico Medicine Added to Hang Seng Biotech Index, Effective 8 June 2026","media":"Bulletin Express","content":"<p>Insilico Medicine Cayman TopCo (Insilico Medicine) announced that Hang Seng Indexes Company Limited will include the company as a constituent of the Hang Seng Biotech Index following its first-quarter 2026 review. The adjustment will be implemented after market close on 5 June 2026 and take effect on 8 June 2026.</p>\n<p>The Hang Seng Biotech Index tracks the performance of the 30 largest biotech companies listed in Hong Kong that are eligible for Southbound Stock Connect trading. Insilico Medicine’s inclusion signals growing market recognition of its long-term growth prospects and is expected to broaden exposure to index-tracking and institutional portfolios, potentially enhancing share liquidity and investor diversification.</p>\n<p>The Board expressed appreciation for shareholder support and reiterated that forward-looking statements are subject to uncertainties. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares. The announcement was dated 26 May 2026 and signed by Chairman, Executive Director, CEO and CBO, Dr. Aleksandrs Zavoronkovs.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico Medicine Added to Hang Seng Biotech Index, Effective 8 June 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico Medicine Added to Hang Seng Biotech Index, Effective 8 June 2026\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-05-26 17:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Insilico Medicine Cayman TopCo (Insilico Medicine) announced that Hang Seng Indexes Company Limited will include the company as a constituent of the Hang Seng Biotech Index following its first-quarter 2026 review. The adjustment will be implemented after market close on 5 June 2026 and take effect on 8 June 2026.</p>\n<p>The Hang Seng Biotech Index tracks the performance of the 30 largest biotech companies listed in Hong Kong that are eligible for Southbound Stock Connect trading. Insilico Medicine’s inclusion signals growing market recognition of its long-term growth prospects and is expected to broaden exposure to index-tracking and institutional portfolios, potentially enhancing share liquidity and investor diversification.</p>\n<p>The Board expressed appreciation for shareholder support and reiterated that forward-looking statements are subject to uncertainties. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares. The announcement was dated 26 May 2026 and signed by Chairman, Executive Director, CEO and CBO, Dr. Aleksandrs Zavoronkovs.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1176084051","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176084051","pubTimestamp":1779786212,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Insilico Medicine Cayman TopCo (Insilico Medicine) announced that Hang Seng Indexes Company Limited will include the company as a constituent of the Hang Seng Biotech Index following its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"英矽智能加入恒生生物科技指数，自2026年6月8日起生效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"Insilico Medicine Cayman TopCo (Insilico Medicine) announced that Hang Seng Indexes Company Limited will include the company as a constituent of the Hang Seng Biotech Index following its first-quarter 2026 review. The adjustment will be implemented after market close on 5 June 2026 and take effect on 8 June 2026.\nThe Hang Seng Biotech Index tracks the performance of the 30 largest biotech companies listed in Hong Kong that are eligible for Southbound Stock Connect trading. Insilico Medicine’s inclusion signals growing market recognition of its long-term growth prospects and is expected to broaden exposure to index-tracking and institutional portfolios, potentially enhancing share liquidity and investor diversification.\nThe Board expressed appreciation for shareholder support and reiterated that forward-looking statements are subject to uncertainties. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares. The announcement was dated 26 May 2026 and signed by Chairman, Executive Director, CEO and CBO, Dr. Aleksandrs Zavoronkovs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}